Related Experiment Video
Updated: Mar 21, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.6K
New therapeutic solutions for Behçet's syndrome
Antonio Vitale1, Donato Rigante2, Giuseppe Lopalco3
1a Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences , University of Siena , Siena , Italy.
Expert Opinion on Investigational Drugs
|May 11, 2016
Summary
Interleukin-1 (IL-1) inhibitors show promise for treating Behçet's syndrome (BS), a complex inflammatory condition. Further research into novel therapies is crucial for managing BS patients unresponsive to current treatments.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Behçet's syndrome (BS) is a systemic inflammatory disorder with diverse clinical features and no definitive treatment.
- BS is increasingly viewed as bridging autoimmune and autoinflammatory conditions, opening new therapeutic avenues.
Purpose of the Study:
- To review current evidence on emerging pharmacological agents for Behçet's syndrome treatment.
- To evaluate the efficacy and safety of novel therapies beyond anti-tumor necrosis factor agents.
Main Methods:
- Systematic review of recent literature on pharmacological treatments for BS.
- Inclusion of agents such as IL-1 inhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon-alpha-2a, and apremilast.
Main Results:
- IL-1 inhibitors are the most studied new agents, demonstrating efficacy, safety, and good treatment retention in BS.
- Several other agents have shown variable but promising results in managing BS manifestations.
Conclusions:
- IL-1 inhibitors represent a significant advancement in BS treatment, offering a safe and effective option.
- Continued investigation into novel therapies is essential for improving outcomes in patients with refractory BS and enhancing their quality of life.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
910
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
910
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
606
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
606
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
722
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
722
01:29Drugs for Treatment of Ulcerative Colitis in IBD
602
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
602
01:26Peptic Ulcer Disease IV: Management
625
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
625
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
655
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
655